Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities
Yang Liu(Dana-Farber Cancer Institute), Franziska Michor(Dana-Farber Cancer Institute)
Cited by 29
Related Papers
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
|Science Translational Medicine|2011|530
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma
|Journal of Clinical Oncology|2017|468
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype
|Journal of Clinical Investigation|2010|331